Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts

Yasuji Mori, Wataru Ishida, Swati Bhattacharyya, Yongzhong Li, Leonidas C. Platanias, John Varga*

*Corresponding author for this work

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Objective. Members of the transforming growth factor β (TGFβ) cytokine superfamily play critical roles in both homeostasis and disease. In light of their profibrotic effects, these molecules are implicated in the pathogenesis of fibrosis. In fibroblasts, TGFβ signals through the activin receptor-like kinase 5 (ALK-5) type I TGFβ and triggers Smad and MAP kinase signaling pathways. Because targeting of TGFβ signaling represents a potential approach to the treatment of systemic sclerosis (SSc) and other fibrotic disorders, we investigated the modulation of intracellular TGFβ signal transduction by SB431542, the first small-molecule inhibitor of ALK-5 to be described. Methods. Ligand-induced activation of the Smad signaling pathway in human dermal fibroblasts was examined by Western blot analysis and confocal immunocytochemistry. Modulation of profibrotic gene expression was investigated using Northern blot analysis, transient transfection assays, and confocal microscopy. Induction of TGFβ production was evaluated by enzyme-linked immumosorbent assay. Results. SB431542 abrogated TGFβ-induced phosphorylation and nuclear importation of endogenous Smad2/3 and Smad4, and inhibited Smad3- and Smad2-dependent gene transcription. Treatment with SB431542 prevented TGFβ-indaced stimulation of collagen, fibronectin, plasminogen activator inhibitor 1, and connective tisseue growth factor gene expression, TGFβ autoinduction, and myofibroblast transdifferentiation, and it could reverse stimulation even when added to the cultures after TGFβ. In contrast, STAT-6-mediated stimulation of collagen gene expression induced by interleukin-13 was not prevented by SB431542, indicating the specificity of blockade for ALK-5-dependent signaling. Furthermore, in contrast to its effects on receptor-activated Smad activation, SB431542 failed to prevent TGFβ-induced activation of MAP kinases. Conclusion. The results indicate that SB431542 is a potent inhibitor of intracellular TGFβ signaling in normal fibroblasts through selective interference with ALK-5-mediated Smad activation and Smad-dependent transcriptional responses. Therefore, SB431542 is useful as a novel experimental tool for gaining a detailed understanding of normal and aberrant TGFβ signaling in SSc. Furthermore, as an anti-TGFβ agent, SB431542 may represent a potential new approach to the treatment of fibrosis.

Original languageEnglish (US)
Pages (from-to)4008-4021
Number of pages14
JournalArthritis and rheumatism
Volume50
Issue number12
DOIs
StatePublished - Dec 1 2004

Fingerprint

Transforming Growth Factors
Fibroblasts
Skin
Systemic Scleroderma
TGF-beta type I receptor
Gene Expression
Fibrosis
Collagen
Myofibroblasts
Interleukin-13
Fibroblast Growth Factors
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
MAP Kinase Signaling System
Plasminogen Activator Inhibitor 1
Fibronectins
Confocal Microscopy
Northern Blotting
Transfection
Signal Transduction
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

@article{67386341a6784cae875f440ee7d146f5,
title = "Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts",
abstract = "Objective. Members of the transforming growth factor β (TGFβ) cytokine superfamily play critical roles in both homeostasis and disease. In light of their profibrotic effects, these molecules are implicated in the pathogenesis of fibrosis. In fibroblasts, TGFβ signals through the activin receptor-like kinase 5 (ALK-5) type I TGFβ and triggers Smad and MAP kinase signaling pathways. Because targeting of TGFβ signaling represents a potential approach to the treatment of systemic sclerosis (SSc) and other fibrotic disorders, we investigated the modulation of intracellular TGFβ signal transduction by SB431542, the first small-molecule inhibitor of ALK-5 to be described. Methods. Ligand-induced activation of the Smad signaling pathway in human dermal fibroblasts was examined by Western blot analysis and confocal immunocytochemistry. Modulation of profibrotic gene expression was investigated using Northern blot analysis, transient transfection assays, and confocal microscopy. Induction of TGFβ production was evaluated by enzyme-linked immumosorbent assay. Results. SB431542 abrogated TGFβ-induced phosphorylation and nuclear importation of endogenous Smad2/3 and Smad4, and inhibited Smad3- and Smad2-dependent gene transcription. Treatment with SB431542 prevented TGFβ-indaced stimulation of collagen, fibronectin, plasminogen activator inhibitor 1, and connective tisseue growth factor gene expression, TGFβ autoinduction, and myofibroblast transdifferentiation, and it could reverse stimulation even when added to the cultures after TGFβ. In contrast, STAT-6-mediated stimulation of collagen gene expression induced by interleukin-13 was not prevented by SB431542, indicating the specificity of blockade for ALK-5-dependent signaling. Furthermore, in contrast to its effects on receptor-activated Smad activation, SB431542 failed to prevent TGFβ-induced activation of MAP kinases. Conclusion. The results indicate that SB431542 is a potent inhibitor of intracellular TGFβ signaling in normal fibroblasts through selective interference with ALK-5-mediated Smad activation and Smad-dependent transcriptional responses. Therefore, SB431542 is useful as a novel experimental tool for gaining a detailed understanding of normal and aberrant TGFβ signaling in SSc. Furthermore, as an anti-TGFβ agent, SB431542 may represent a potential new approach to the treatment of fibrosis.",
author = "Yasuji Mori and Wataru Ishida and Swati Bhattacharyya and Yongzhong Li and Platanias, {Leonidas C.} and John Varga",
year = "2004",
month = "12",
day = "1",
doi = "10.1002/art.20658",
language = "English (US)",
volume = "50",
pages = "4008--4021",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts

AU - Mori, Yasuji

AU - Ishida, Wataru

AU - Bhattacharyya, Swati

AU - Li, Yongzhong

AU - Platanias, Leonidas C.

AU - Varga, John

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Objective. Members of the transforming growth factor β (TGFβ) cytokine superfamily play critical roles in both homeostasis and disease. In light of their profibrotic effects, these molecules are implicated in the pathogenesis of fibrosis. In fibroblasts, TGFβ signals through the activin receptor-like kinase 5 (ALK-5) type I TGFβ and triggers Smad and MAP kinase signaling pathways. Because targeting of TGFβ signaling represents a potential approach to the treatment of systemic sclerosis (SSc) and other fibrotic disorders, we investigated the modulation of intracellular TGFβ signal transduction by SB431542, the first small-molecule inhibitor of ALK-5 to be described. Methods. Ligand-induced activation of the Smad signaling pathway in human dermal fibroblasts was examined by Western blot analysis and confocal immunocytochemistry. Modulation of profibrotic gene expression was investigated using Northern blot analysis, transient transfection assays, and confocal microscopy. Induction of TGFβ production was evaluated by enzyme-linked immumosorbent assay. Results. SB431542 abrogated TGFβ-induced phosphorylation and nuclear importation of endogenous Smad2/3 and Smad4, and inhibited Smad3- and Smad2-dependent gene transcription. Treatment with SB431542 prevented TGFβ-indaced stimulation of collagen, fibronectin, plasminogen activator inhibitor 1, and connective tisseue growth factor gene expression, TGFβ autoinduction, and myofibroblast transdifferentiation, and it could reverse stimulation even when added to the cultures after TGFβ. In contrast, STAT-6-mediated stimulation of collagen gene expression induced by interleukin-13 was not prevented by SB431542, indicating the specificity of blockade for ALK-5-dependent signaling. Furthermore, in contrast to its effects on receptor-activated Smad activation, SB431542 failed to prevent TGFβ-induced activation of MAP kinases. Conclusion. The results indicate that SB431542 is a potent inhibitor of intracellular TGFβ signaling in normal fibroblasts through selective interference with ALK-5-mediated Smad activation and Smad-dependent transcriptional responses. Therefore, SB431542 is useful as a novel experimental tool for gaining a detailed understanding of normal and aberrant TGFβ signaling in SSc. Furthermore, as an anti-TGFβ agent, SB431542 may represent a potential new approach to the treatment of fibrosis.

AB - Objective. Members of the transforming growth factor β (TGFβ) cytokine superfamily play critical roles in both homeostasis and disease. In light of their profibrotic effects, these molecules are implicated in the pathogenesis of fibrosis. In fibroblasts, TGFβ signals through the activin receptor-like kinase 5 (ALK-5) type I TGFβ and triggers Smad and MAP kinase signaling pathways. Because targeting of TGFβ signaling represents a potential approach to the treatment of systemic sclerosis (SSc) and other fibrotic disorders, we investigated the modulation of intracellular TGFβ signal transduction by SB431542, the first small-molecule inhibitor of ALK-5 to be described. Methods. Ligand-induced activation of the Smad signaling pathway in human dermal fibroblasts was examined by Western blot analysis and confocal immunocytochemistry. Modulation of profibrotic gene expression was investigated using Northern blot analysis, transient transfection assays, and confocal microscopy. Induction of TGFβ production was evaluated by enzyme-linked immumosorbent assay. Results. SB431542 abrogated TGFβ-induced phosphorylation and nuclear importation of endogenous Smad2/3 and Smad4, and inhibited Smad3- and Smad2-dependent gene transcription. Treatment with SB431542 prevented TGFβ-indaced stimulation of collagen, fibronectin, plasminogen activator inhibitor 1, and connective tisseue growth factor gene expression, TGFβ autoinduction, and myofibroblast transdifferentiation, and it could reverse stimulation even when added to the cultures after TGFβ. In contrast, STAT-6-mediated stimulation of collagen gene expression induced by interleukin-13 was not prevented by SB431542, indicating the specificity of blockade for ALK-5-dependent signaling. Furthermore, in contrast to its effects on receptor-activated Smad activation, SB431542 failed to prevent TGFβ-induced activation of MAP kinases. Conclusion. The results indicate that SB431542 is a potent inhibitor of intracellular TGFβ signaling in normal fibroblasts through selective interference with ALK-5-mediated Smad activation and Smad-dependent transcriptional responses. Therefore, SB431542 is useful as a novel experimental tool for gaining a detailed understanding of normal and aberrant TGFβ signaling in SSc. Furthermore, as an anti-TGFβ agent, SB431542 may represent a potential new approach to the treatment of fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=10444259759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10444259759&partnerID=8YFLogxK

U2 - 10.1002/art.20658

DO - 10.1002/art.20658

M3 - Article

C2 - 15593186

AN - SCOPUS:10444259759

VL - 50

SP - 4008

EP - 4021

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -